Impact of Myc-Altered Pathology on Radiotherapy Efficacy Among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Study by XXX: Impact of double hit pathology on RT efficacy.

Yolanda D Tseng, Phil Stevenson, Bachviet Nguyen, Davey C Li, Daniel Lee, Ima Paydar, Justyn Nakashima, Alex Balogh, Revathi Ravella, Andrew B Barbour, Carl Post, Hazim Ababneh, Chelsea C Pinnix, Leslie K Ballas, Michael S Binkley, Katerina Dedeckova, Richard T Hoppe, Chirayu Patel, Nima Nabavizadeh, Christopher R Kelsey, Kiran A Kumar, Daniel Landsburg, Nicholas Figura, Andrea C Lo, John P Plastaras
{"title":"Impact of Myc-Altered Pathology on Radiotherapy Efficacy Among Patients with Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Study by XXX: Impact of double hit pathology on RT efficacy.","authors":"Yolanda D Tseng, Phil Stevenson, Bachviet Nguyen, Davey C Li, Daniel Lee, Ima Paydar, Justyn Nakashima, Alex Balogh, Revathi Ravella, Andrew B Barbour, Carl Post, Hazim Ababneh, Chelsea C Pinnix, Leslie K Ballas, Michael S Binkley, Katerina Dedeckova, Richard T Hoppe, Chirayu Patel, Nima Nabavizadeh, Christopher R Kelsey, Kiran A Kumar, Daniel Landsburg, Nicholas Figura, Andrea C Lo, John P Plastaras","doi":"10.1016/j.ijrobp.2024.11.072","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Presence of MYC and BCL2 translocations (i.e. double-hit lymphoma, DHL) in large B-cell lymphoma (LBCL) is associated with reduced chemosensitivity, but less is known on its impact on radiotherapy (RT) efficacy.</p><p><strong>Methods/materials: </strong>Patients with LBCL that received their first course of RT for relapsed/refractory (r/r) disease between 2008-2020 were eligible if there was adequate pathologic evaluation to be categorized as DHL versus non-DHL as per WHO (5<sup>th</sup> edition). Separate analyses were conducted by treatment intent. Predictors for response (complete and partial) and local recurrence (LR) were evaluated using Cox regression analysis. LR analysis was restricted to curative-intent patients to ensure adequate follow-up.</p><p><strong>Results: </strong>383 patients (102 DHL, 281 non-DHL, 44% curative) were treated to 447 sites. Median time from diagnosis to RT was 11.6 months, with 38.7% patients having primary chemorefractory disease, 37.4% having received >2 lines of systemic therapy, and 24% status post stem cell transplant. Median biological equivalent dose (alpha/beta 10) was 28 Gy (range 3.2-60.0) for palliative and 46.9 Gy (range 6.4-84.0) for curative-intent patients. With a median follow-up of 41.1 and 41.5 months among curative and palliative patients, respectively, response was high (81.1% curative, 60.1% palliative). On univariate analysis, DHL pathology was not associated with RT response in either curative or palliative patients. Among curative patients, 2-year LR rate was 38.8%. On multivariable analysis, DHL pathology was associated with a 2 times higher risk of LR (95% CI 1.05-3.67,p=.03), with a crude LR rate of 42.9% (DHL) versus 28.9% (non-DHL). RT was well tolerated with low rates of grade 3 or higher acute toxicity (1.8% curative, 2.9% palliative).</p><p><strong>Conclusions: </strong>Relapsed/refractory LBCL remains radioresponsive with 60-80% response rate to RT. While DHL pathology does not appear to influence RT response, its presence is associated with higher rates of local recurrence, suggesting it may be more radioresistant.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.11.072","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Presence of MYC and BCL2 translocations (i.e. double-hit lymphoma, DHL) in large B-cell lymphoma (LBCL) is associated with reduced chemosensitivity, but less is known on its impact on radiotherapy (RT) efficacy.

Methods/materials: Patients with LBCL that received their first course of RT for relapsed/refractory (r/r) disease between 2008-2020 were eligible if there was adequate pathologic evaluation to be categorized as DHL versus non-DHL as per WHO (5th edition). Separate analyses were conducted by treatment intent. Predictors for response (complete and partial) and local recurrence (LR) were evaluated using Cox regression analysis. LR analysis was restricted to curative-intent patients to ensure adequate follow-up.

Results: 383 patients (102 DHL, 281 non-DHL, 44% curative) were treated to 447 sites. Median time from diagnosis to RT was 11.6 months, with 38.7% patients having primary chemorefractory disease, 37.4% having received >2 lines of systemic therapy, and 24% status post stem cell transplant. Median biological equivalent dose (alpha/beta 10) was 28 Gy (range 3.2-60.0) for palliative and 46.9 Gy (range 6.4-84.0) for curative-intent patients. With a median follow-up of 41.1 and 41.5 months among curative and palliative patients, respectively, response was high (81.1% curative, 60.1% palliative). On univariate analysis, DHL pathology was not associated with RT response in either curative or palliative patients. Among curative patients, 2-year LR rate was 38.8%. On multivariable analysis, DHL pathology was associated with a 2 times higher risk of LR (95% CI 1.05-3.67,p=.03), with a crude LR rate of 42.9% (DHL) versus 28.9% (non-DHL). RT was well tolerated with low rates of grade 3 or higher acute toxicity (1.8% curative, 2.9% palliative).

Conclusions: Relapsed/refractory LBCL remains radioresponsive with 60-80% response rate to RT. While DHL pathology does not appear to influence RT response, its presence is associated with higher rates of local recurrence, suggesting it may be more radioresistant.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
复发/难治性大B细胞淋巴瘤患者的Myc改变病理对放疗疗效的影响:XXX合作研究:双击病理对RT疗效的影响。
目的:大B细胞淋巴瘤(LBCL)中存在MYC和BCL2易位(即双命中淋巴瘤,DHL)与化疗敏感性降低有关,但其对放疗(RT)疗效的影响却鲜为人知:2008-2020年间,因复发/难治性(r/r)疾病而接受首个RT疗程的大B细胞淋巴瘤患者,如果根据WHO(第5版)有足够的病理评估可分为DHL和非DHL,则符合条件。按治疗意向分别进行分析。采用 Cox 回归分析评估了反应(完全反应和部分反应)和局部复发(LR)的预测因素。LR分析仅限于治疗意向患者,以确保充分的随访:383例患者(102例DHL,281例非DHL,44%治愈)接受了447个部位的治疗。从确诊到接受RT治疗的中位时间为11.6个月,38.7%的患者患有原发性化疗难治性疾病,37.4%的患者接受过2种以上的系统治疗,24%的患者处于干细胞移植后状态。姑息患者的中位生物等效剂量(α/β 10)为28 Gy(范围3.2-60.0),治愈患者的中位生物等效剂量为46.9 Gy(范围6.4-84.0)。治愈患者和姑息患者的中位随访时间分别为 41.1 个月和 41.5 个月,患者反应良好(81.1% 为治愈,60.1% 为姑息)。单变量分析显示,无论是治愈患者还是姑息患者,DHL病理与RT反应无关。在治愈患者中,2年LR率为38.8%。在多变量分析中,DHL病理与高出2倍的LR风险相关(95% CI 1.05-3.67,p=.03),粗LR率为42.9%(DHL)对28.9%(非DHL)。RT耐受性良好,3级或以上急性毒性发生率较低(1.8%治愈,2.9%缓解):结论:复发/难治性LBCL仍然具有放射反应性,对RT的反应率为60-80%。虽然DHL病理似乎并不影响RT反应,但它的存在与较高的局部复发率有关,表明它可能更具放射抗性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
Docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial cancer after staging surgery: a phase II study. Exploratory Evaluation of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR) with CNS-Active Drugs in Brain Metastases Treatment. Generalizable MRI-based Nasopharyngeal Carcinoma Delineation: Bridging Gaps across Multiple Centers and Raters with Active Learning. Ten-year outcomes of a phase III, multicenter, randomized controlled trial (SHIP0804) with three-month neoadjuvant androgen deprivation prior to 125I-seed transperineal prostate brachytherapy followed by nil versus nine-month adjuvant hormonal therapy in patients with intermediate-risk prostate cancer. Constructing Surrogate Lung Ventilation Maps from 4DCT-derived Subregional Respiratory Dynamics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1